Recent advances in non-small cell lung cancer targeted therapy; an update review

Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last decade, significant advancements in the diagnosis and treatment of lung cancer, particularly NSCLC, have been achieved with the help of molecular translational research. Among the hopeful breakthroughs in therapeutic approaches, advances in targeted therapy have brought the most successful outcomes in NSCLC treatment. In targeted therapy, antagonists target the specific genes, proteins, or the microenvironment of tumors supporting cancer growth and survival. Indeed, cancer can be managed by blocking the target genes related to tumor cell progression without causing noticeable damage to normal cells. Currently, efforts have been focused on improving the targeted therapy aspects regarding the encouraging outcomes in cancer treatment and the quality of life of patients. Treatment with targeted therapy for NSCLC is changing rapidly due to the pace of scientific research. Accordingly, this updated study aimed to discuss the tumor target antigens comprehensively and targeted therapy-related agents in NSCLC. The current study also summarized the available clinical trial studies for NSCLC patients.

Automated summary

Lung cancer is the leading cause of cancer-related death globally, and significant advancements have been made in the last decade in diagnosing and treating NSCLC through molecular translational research. Targeted therapy, specifically aimed at specific genes, proteins, or the tumor microenvironment, has shown the most successful outcomes in NSCLC treatment. Efforts are currently focused on improving targeted therapy to enhance cancer treatment outcomes and patient quality of life. This updated study provides a comprehensive discussion on tumor target antigens and targeted therapy-related agents, along with a summary of available clinical trial studies for NSCLC patients.